Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months
- Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months
- Lonza’s Ibex™ Develop will enable Genmab to support their expanding pipeline demand for product across all clinical phases and towards potential launch
- Flexible asset management designed to provide secure capacity for Genmab across their portfolio of candidates
Quote from Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech:
”Extending this trusted relationship with Genmab is a great motivation for our teams who have been working together for a number of years. Genmab’s extensive pipeline is an opportunity for us to combine the speed and flexibility of our Ibex Solutions with the know-how needed to manufacture pioneering molecular formats.”
Basel, Switzerland, October 14, 2019 – Lonza today announced an extension to its partnership with Genmab to cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline. Lonza’s Ibex Solutions in Visp (CH) is designed to provide Genmab with the flexibility and speed they need to take their candidates towards IND and commercialization.
Genmab and Lonza have a longstanding relationship, having worked together on multiple antibody-based programs since 2002.
Lonza’s Ibex Design offering enables Genmab to take their candidates from gene to IND in 12 months and then move to reserved manufacturing capacity in Ibex Develop for clinical manufacturing and BLA submission when Genmab needs it. The agreement aims to provide Genmab with security of supply and to enable Genmab to move rapidly into clinical manufacturing with the flexibility needed to manage an extensive pipeline through the demands of clinical trials.
The new agreement will cover development and clinical manufacturing of drug substance and drug product for certain programs in Genmab’s pre-clinical and clinical pipeline. These include more complex molecular formats developed using Genmab’s DuoBody® technology.
Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ media@lonza.com
About Lonza Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma, Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at lonza.com
Lonza Contact Details
Dirk Oehlers Investor Relations Officer Lonza Group Ltd Tel +41 61 316 8540 dirk.oehlers@lonza.com
Dr. Sanna Fowler Head of External Communications Lonza Group Ltd Tel +41 61 316 8929 sanna.fowler@lonza.com
Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release
